Regulation of bile acids and their receptor FXR in metabolic diseases

Yao Li, Lulu Wang, Yi Qing, Liping Luo, Yuxia XiongFrontiers in Nutrition 2024 · DOI

Abstract

High sugar, high-fat diets and unhealthy lifestyles have led to an epidemic of obesity and obesity-related metabolic diseases, seriously placing a huge burden on socio-economic development. A deeper understanding and elucidation of the specific molecular biological mechanisms underlying the onset and development of obesity has become a key to the treatment of metabolic diseases. Recent studies have shown that the changes of bile acid composition are closely linked to the development of metabolic diseases. Bile acids can not only emulsify lipids in the intestine and promote lipid absorption, but also act as signaling molecules that play an indispensable role in regulating bile acid homeostasis, energy expenditure, glucose and lipid metabolism, immunity. Disorders of bile acid metabolism are therefore important risk factors for metabolic diseases. The farnesol X receptor, a member of the nuclear receptor family, is abundantly expressed in liver and intestinal tissues. Bile acids act as endogenous ligands for the farnesol X receptor, and erroneous FXR signaling triggered by bile acid dysregulation contributes to metabolic diseases, including obesity, non-alcoholic fatty liver disease and diabetes. Activation of FXR signaling can reduce lipogenesis and inhibit gluconeogenesis to alleviate metabolic diseases. It has been found that intestinal FXR can regulate hepatic FXR in an organ-wide manner. The crosstalk between intestinal FXR and hepatic FXR provides a new idea for the treatment of metabolic diseases. This review focuses on the relationship between bile acids and metabolic diseases and the current research progress to provide a theoretical basis for further research and clinical applications.

Introduction: The Metabolic Crisis and the Gut-Liver Axis

Metabolic diseases like non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) have reached epidemic proportions, yet therapeutic toolkits remain limited. While researchers have long recognized bile acids (BAs) for their role in fat emulsification, recent evidence highlights their function as systemic hormones.

The central challenge is the "tissue-specificity paradox" of the farnesoid X receptor (FXR). While activating FXR in the liver generally improves lipid profiles, activating it in the intestine can have divergent effects on glucose production and fat absorption. This review synthesizes current research to clarify how bile acid dysregulation contributes to disease and how precise organ-specific targeting of FXR might restore metabolic balance.

Methods

This comprehensive review synthesizes findings from 159 peer-reviewed studies, ranging from molecular signaling assays to mouse models and human clinical trials. The analysis focuses on:

  • Biosynthetic Pathways: Comparing the "classical" (neutral) and "alternative" (acidic) pathways of bile acid synthesis.
  • Signaling Cascades: Mapping the FXR-SHP and FXR-FGF15/19 axes that facilitate communication between the gut and the liver.
  • Microbiome Interactions: Analyzing how bacterial enzymes like bile salt hydrolase (BSH) modify the bile acid pool, thereby modulating FXR signaling.
Synthesis and metabolism of bile acids via the gut-liver axis.

Key Insights: Bile Acids as Metabolic Rheostats

Bile acids act as endogenous ligands for FXR. Upon binding, they trigger a cascade that inhibits their own synthesis via a negative feedback loop while simultaneously regulating genes involved in fatty acid oxidation and gluconeogenesis.

The Gut-Liver Relay

Intestinal FXR activation triggers the release of Fibroblast Growth Factor 15/19 (FGF15 in mice, FGF19 in humans). This hormone travels through the portal vein to the liver, binding to FGFR4 to shut down bile acid synthesis, effectively acting as a long-distance metabolic switch.

The Microbiome as a Gatekeeper

The gut microbiota determines the composition of the bile acid pool. Bacteria with BSH enzymes deconjugate bile acids, changing them from FXR agonists (activators) to antagonists (inhibitors). Consequently, the state of the gut flora directly dictates hepatic metabolic signaling.

Key Results in Glycolipid Homeostasis

FXR activation plays a dual role in managing lipids and glucose:

  • Lipid Regulation: FXR reduces hepatic lipogenesis by inhibiting SREBP-1c and promotes fatty acid oxidation via PPAR-$\alpha$, significantly reducing triglyceride accumulation.
  • Glucose Homeostasis: FXR negatively regulates key gluconeogenic enzymes such as PEPCK, G6Pase, and FBP1. In diabetic rat models, treatment with the FXR agonist CDCA reversed elevated blood glucose levels.
  • Inflammation Suppression: FXR activation in immune cells (macrophages and DCs) inhibits the NF-$\kappa$B pathway, reducing the release of pro-inflammatory cytokines like IL-1$\beta$ and IL-6.
FXR regulation of glycolipid homeostasis in the liver and intestine.

Limitations and Future Directions

Translating these findings into clinical practice faces several hurdles:

  • Species Divergence: Mice produce $\alpha/\beta$-muricholic acids (natural FXR antagonists), which humans do not, making mouse-to-human translation difficult.
  • Systemic Side Effects: Non-tissue-specific agonists can have paradoxical effects, sometimes exacerbating weight gain or insulin resistance.
  • The Need for Precision: Future metabolic therapy lies in "organ-wide" regulation—developing drugs that selectively target intestinal vs. hepatic FXR. Further research is required to map the exact molecular triggers that cause FXR to behave differently across various cell types, such as L-cells versus $\beta$-cells.

Summary updated

Abstract

High sugar, high-fat diets and unhealthy lifestyles have led to an epidemic of obesity and obesity-related metabolic diseases, seriously placing a huge burden on socio-economic development. A deeper understanding and elucidation of the specific molecular biological mechanisms underlying the onset and development of obesity has become a key to the treatment of metabolic diseases. Recent studies have shown that the changes of bile acid composition are closely linked to the development of metabolic diseases. Bile acids can not only emulsify lipids in the intestine and promote lipid absorption, but also act as signaling molecules that play an indispensable role in regulating bile acid homeostasis, energy expenditure, glucose and lipid metabolism, immunity. Disorders of bile acid metabolism are therefore important risk factors for metabolic diseases. The farnesol X receptor, a member of the nuclear receptor family, is abundantly expressed in liver and intestinal tissues. Bile acids act as endogenous ligands for the farnesol X receptor, and erroneous FXR signaling triggered by bile acid dysregulation contributes to metabolic diseases, including obesity, non-alcoholic fatty liver disease and diabetes. Activation of FXR signaling can reduce lipogenesis and inhibit gluconeogenesis to alleviate metabolic diseases. It has been found that intestinal FXR can regulate hepatic FXR in an organ-wide manner. The crosstalk between intestinal FXR and hepatic FXR provides a new idea for the treatment of metabolic diseases. This review focuses on the relationship between bile acids and metabolic diseases and the current research progress to provide a theoretical basis for further research and clinical applications.
BibTeX
@inproceedings{li2024regulation,
  author = {Yao Li and Lulu Wang and Yi Qing and Liping Luo and Yuxia Xiong},
  title = {{Regulation of bile acids and their receptor FXR in metabolic diseases}},
  booktitle = {Frontiers in Nutrition},
  year = {2024},
  doi = {10.3389/fnut.2024.1447878},
}
Figure